Roche ramps up immunotherapy R&DSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. more ➔
Roche ramps up immunotherapy R&DSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. more ➔
Roche ramps up immunotherapy R&DSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. more ➔
Roche ramps up immunotherapy R&DSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. more ➔
Roche ramps up immunotherapy R&DSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. more ➔
Roche ramps up immunotherapy R&DSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. more ➔
Adaptimmune downgrades trial design after...Oxford-based immuno-oncology play Adaptimmune has been obliged by the FDA to alter the trial design of a Phase I/II study in patients with MRCLS. A partial clinical hold was lifted now. more ➔
Multiple sclerosis diagnosis in early stag...Belgian and German researchers have presented a new imaging tool that can track immune cells invading the brain in the initial stages of multiple sclerosis (MS). more ➔
BIO Europe with new record numbers Despite declining numbers of IPOs, financing rounds and licensing deals, the European biotech sector presented itself optimistic and self-confident during BIO-Europe in Cologne. The three-days partnering … more ➔
AZ withdraws lung cancer drug from EU lead...After AstraZeneca removed its NSCLC drug osimertinib from the German market following a benefit assessment of German health technology assessor G-BA negatively impacting price negotiations, the German … more ➔
